The biotech scorecard for the first quarter: 19 stock-moving events to watch

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial. This quarter, the company hopes to follow up those positive results with the readout of a second, Phase 3 study.

Genetic medicine is expected to have an eventful year, starting with regulatory submissions for two competing treatments for sickle cell disease. Vertex Pharmaceuticals and its partner CRISPR Therapeutics will be completing an FDA marketing application for their CRISPR-based treatment called exa-cel. Gene therapy maker Bluebird Bio will be doing the same with its treatment called lovo-cel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In